Clinical Report: FDA Approves First Therapy to Reduce Pancreatitis Risk
Overview
The FDA has approved olezarsen (Tryngolza) to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia. This approval is based on two randomized trials.
Background
Severe hypertriglyceridemia is defined as fasting triglyceride levels of at least 500 mg/dL. The approval of olezarsen represents a new therapeutic option for managing this condition.
Data Highlights
| Trial | 50 mg Dose Reduction | 80 mg Dose Reduction |
|---|---|---|
| Trial 1 | 63% | 72% |
| Trial 2 | 49% | 55% |
Key Findings
- Olezarsen is approved to reduce triglycerides and pancreatitis risk in severe hypertriglyceridemia.
- Mean baseline triglyceride levels in trials were 1,116 mg/dL.
- Reductions in triglyceride levels were observed: 63% and 72% in Trial 1, and 49% and 55% in Trial 2.
- A pooled analysis indicated a lower incidence of acute pancreatitis with olezarsen compared to placebo.
- Common adverse reactions included injection-site reactions and increased liver enzyme levels.
- Healthcare providers are advised to monitor liver enzymes before and during treatment.
Clinical Implications
Healthcare providers should monitor liver enzyme elevations before and during treatment.
Conclusion
Olezarsen has been approved for managing severe hypertriglyceridemia.
Related Resources & Content
- US Food and Drug Administration, FDA, 2024 -- FDA Approves First Therapy to Reduce Pancreatitis Risk
- The New Gastroenterologist — Endoscopic Sphincterotomy of the Minor Papilla Does Not Decrease Risks in Patients with Pancreas Divisum
- conexiant — FDA Approves Device for Pancreas Care
- conexiant — GLP-1 RAs Show Mixed Pancreatitis Risk
- Surgical Endoscopy — Efficacy of intravenous parecoxib in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial
- Endoscopic Sphincterotomy of the Minor Papilla Does Not Decrease Risks in Patients with Pancreas Divisum
- FDA Approves Device for Pancreas Care
- GLP-1 RAs Show Mixed Pancreatitis Risk
- TRYNGOLZA (olezarsen) injection, for subcutaneous use
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation
- BRIDGE-TIMI 73a: Novel Olezarsen Reduces Triglycerides, ApoC3, ApoB Levels - American College of Cardiology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
